Notification of transactions by Primary Insiders (grant options)
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-06-13 12:09:49
In connection with the re-election of Jonathan Allis to the board of directors
of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been
granted 569,370 options in the Company which will vest on a quarterly basis.
With the addition of the 63,263 options previously granted, Mr. Allis now has a
total of 632,633 options.
Please see the attached notification form for further information.
This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com